IBA – Transparency Notification

Louvain-la-Neuve, Belgium, May 05, 2020, 17.30

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on May 05, 2020.

In its notification, Institut National des Radioéléments F.U.P. has notified, that following a passive threshold crossing, its total holding in IBA has crossed upwards the 5 % threshold on April 30, 2020.

In details, on April 30, 2020, Institut Nationald des Radioélélements F.U.P. owned 2.846.542 IBA shares with voting rights, representing 7,47 % of the total number of shares issued by IBA (38.085.047).

Content of the notification

• Reason for the notification: Passive threshold crossing
• Persons subject to the notification requirement: Institut National des Radioéléments F.U.P.
• Date on which the threshold is crossed: 30/04/20
• Threshold crossed (in %): 5%
• Denominator: 38 085 047

• Notified details: (extract of the received notification form)

           

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Institut National des Radioéléments F.U.P.
	TOTAL	2.846.542	0	7.47%	0,00%
B) Equivalent financial instruments	After the transaction
Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%
	TOTAL (A & B)			# of voting rights	%of voting rights
				2.846.542	7.47%

For further information, please contact:

IBA

Elodie Jaumain
Paralegal
[phone]

[e-mail]

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Attachments

• 20200505transparencyIRE-FR(au-dessus5%)
• 20200505transparencyIRE-EN(au-dessus5%)